Dexcom vs Moderna (DXCM vs MRNA)
Dexcom (DXCM) vs Moderna (MRNA) in plain English: P/E, growth, margins, debt and dividend side by side, key differences and which fits each investor profile.
Dexcom (DXCM) and Moderna (MRNA) compete in healthcare and pharma. Here are Dexcom and Moderna side by side with their real figures as of November 4, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Dexcom or Moderna.
Dexcom vs Moderna: the figures
| Figure | Dexcom | Moderna |
|---|---|---|
| Share price | $88.48 (November 4, 2026) | $258.38 (November 4, 2026) |
| Market cap | $33.0 billion | $103.2 billion |
| P/E (TTM) | 34.8x | N/A |
| Forward P/E | 28.2x | N/A |
| Revenue growth (quarter) | +11.2% | +2.1% |
| Net margin (TTM) | 19.4% | -141.4% |
| Net debt / EBITDA | Net cash | N/A |
| Dividend yield | 0.00% | 0.00% |
| Beta | 1.44 | 1.17 |
Dexcom and Moderna figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026; N/A means that Dexcom or Moderna figure is not available, and we never estimate it.
3 key differences between Dexcom and Moderna
- Profitability: for every 100 of sales, Dexcom keeps 19.4 as net profit and Moderna keeps -141.4.
- Growth: Dexcom grew sales +11.2% year on year in its latest quarter, against +2.1% for Moderna.
- Size: Moderna is worth $103.2 billion on the stock market, about 3.1 times Dexcom ($33.0 billion).
Dexcom or Moderna: which fits your profile
- If you want growth: Dexcom is growing faster today, so it fits better with investors who put business growth first, usually accepting a higher P/E and a bumpier ride.
- If you prefer caution: Moderna has a less volatile share price, which usually gives more room in a bad year.
Neither Dexcom nor Moderna wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.
How Dexcom and Moderna make money
Dexcom (DXCM)
Dexcom makes continuous glucose monitors, small sensors worn on the skin that send blood sugar readings to a phone. Most revenue comes from disposable sensors that people with diabetes replace regularly, sold through distributors and pharmacies, and it also offers the over-the-counter Stelo. The United States is its largest market. Full Dexcom analysis.
Moderna (MRNA)
Moderna develops messenger RNA vaccines and medicines. Nearly all of its sales come from respiratory vaccines: Spikevax and mNEXSPIKE for covid and mRESVIA for RSV. It sells to governments, health systems and pharmacies, mainly in the United States and Europe, and funds clinical trials in cancer and rare diseases. Full Moderna analysis.
Frequently asked questions: Dexcom vs Moderna
Is Dexcom or Moderna the better stock?
Choosing between Dexcom and Moderna depends on what you are looking for. Dexcom is growing faster right now. Fintols does not tell you whether to buy Dexcom or Moderna: it shows you the differences so you can decide.
Which pays a higher dividend, Dexcom or Moderna?
Neither pays a dividend as of November 4, 2026: Dexcom and Moderna put what they earn into growth or other forms of shareholder return.
Can I own both Dexcom and Moderna?
Yes. Many people spread their money across several companies, such as Dexcom and Moderna, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Dexcom or Moderna.
More comparisons with Dexcom or Moderna
More companies like Dexcom and Moderna: healthcare and pharma stocks. Educational content about Dexcom and Moderna, not investment advice.